Myocardial dysfunction caused by abemaciclib: a case report

Oyakawa, Takuya; Inagaki, Lina; Hua, Zhensheng; Ebihara, Aya; Takano, Toshimi; Ohno, Shinji; Shiga, Taro

doi:10.1007/s13691-021-00500-3

Cited by 4 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One case of myocardial dysfunction has been reported with abemaciclib, associated with a reversible reduction in LVEF. 7 One report found that CDK4/6 inhibitors may increase vascular inflammation, increase hypertension, alter left ventricle geometry and that individuals on these medications should be closely monitored for adverse cardiac outcomes. 8 In vitro, abemaciclib has been found to induce apoptosis, inhibiting cell viability and proliferation of cardiomyocytes which may lead to cardiac adverse events.…”

Section: Discussionmentioning

confidence: 99%

Elevated transaminases and development of cardiomyopathy in a 32-year-old woman with metastatic breast cancer after treatment with ribociclib followed by palbociclib

Watts

Nadori

2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Cyclin-dependent kinase 4 and 6 inhibitors, ribociclib and palbociclib, are associated with reports of transaminitis and adverse cardiac events. Case report The patient is a previously healthy 32-year-old female diagnosed with estrogen receptor-positive, progesterone receptor-positive, and human epidermal growth factor 2 negative metastatic breast cancer. From July to September 2021, the patient was initiated on ribociclib followed by palbociclib for metastatic breast cancer. She subsequently experienced two episodes of transaminitis and was diagnosed with cardiomyopathy. Management and outcome The patient experienced transaminitis 2 weeks after the initiation of ribociclib resulting in discontinuation. When rechallenged with palbociclib, the patient experienced transaminitis within 1 week of initiation, which resulted in discontinuation. Approximately 1 month after palbociclib discontinuation, the patient was diagnosed with congestive heart failure with a left ventricular ejection fraction of 24%. Discussion To our knowledge, there are few case studies investigating cyclin-dependent kinase 4 and 6 inhibitor rechallenge following transaminitis. Prior literature suggests that transaminitis with cyclin-dependent kinase 4 and 6 inhibitors is not a class effect, but this case report suggests otherwise. This report presents a rare case of cardiomyopathy and transaminitis following the administration of cyclin-dependent kinase 4 and 6 inhibitors, ribociclib and palbociclib.

show abstract

Section: Discussionmentioning

confidence: 99%

Elevated transaminases and development of cardiomyopathy in a 32-year-old woman with metastatic breast cancer after treatment with ribociclib followed by palbociclib

Watts

Nadori

2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…In addition, the patient's symptoms were resolved after the ABE therapy was discontinued. [ 10 ] In another study on the use of ABE, ABE was reported to inhibit cell viability and proliferation in the AC16 cell line (human cardiomyocyte cells), and to induce apoptosis in cardiomyocytes by activating the apoptotic signaling pathway. [ 24 ] The mechanism that may cause damage to cardiomyocytes may trigger cardiac dysfunctions in the future.…”

Section: Discussionmentioning

confidence: 99%

“…These studies suggest the need to introduce new preventive approaches against cardiotoxicity from ABE. [10] In experimental studies, curcumin (CUR) has been shown to have therapeutic potential as an anti-inflammatory, antidiabetic, anticancer, and antiaging agent. [11,12] Breast cancer is the second leading cause of cancer-related deaths among women worldwide.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The protective effect of curcumin on cardiac markers and fibrosis in abemaciclib‐induced cardiac damage in rats

Huyut

Uçar

Yıldızhan

et al. 2022

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Abemaciclib (ABE) is a cyclin‐dependent kinase inhibitor used in combination with an antiestrogen in the treatment of breast cancer. In addition to the important therapeutic properties of this drug, its side effects are not fully known. In this study, we aimed to investigate the protective effect of curcumin (CUR) on cardiac damage caused by ABE administration. Forty rats were equally divided into control, dimethyl sulfoxide (150 µL), CUR (30 mg/kg/day), ABE (26 mg/kg/day), and ABE + CUR (26 mg/kg/day ABE and 30mg/kg/day CUR) groups (n = 8). Injections were administered daily for 28 days. Troponin‐I, total cholesterol, and creatine kinase myocardial band (CK‐MB) levels and cardiac fibrosis were higher in the ABE group than in the control group (p < 0.05), and were lower in the ABE + CUR group than in the ABE group (p < 0.05). The results showed that ABE administration can cause cardiac damage and increase cardiac fibrosis. However, they showed that coadministration of CUR with ABE could suppress increases in CK‐MB, troponin‐I, and total cholesterol levels and also cardiac fibrosis associated with cardiac damage. Therefore, we can infer that the subsequent administration of CUR ABE treatment can be used as a therapeutic strategy for preventing cardiac damage.

show abstract

Abemaciclib/bevacizumab/paclitaxel

2021

Reactions Weekly

View full text Add to dashboard Cite

Myocardial dysfunction caused by abemaciclib: a case report

Cited by 4 publications

References 18 publications

Elevated transaminases and development of cardiomyopathy in a 32-year-old woman with metastatic breast cancer after treatment with ribociclib followed by palbociclib

Elevated transaminases and development of cardiomyopathy in a 32-year-old woman with metastatic breast cancer after treatment with ribociclib followed by palbociclib

The protective effect of curcumin on cardiac markers and fibrosis in abemaciclib‐induced cardiac damage in rats

Abemaciclib/bevacizumab/paclitaxel

Contact Info

Product

Resources

About